Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M<sup>pro</sup> Inhibitors-Reference-Cited by-同舟云学术

Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M^pro Inhibitors

Published:2023-09-28 Issue:10 Volume:14 Page:1434-1440
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Jacobs Leon¹,van der Westhuyzen Aletta¹,Pribut Nicole¹^ORCID,Dentmon Zackery W.¹,Cui Dan²,D’Erasmo Michael P.¹,Bartsch Perry W.¹,Liu Ken¹,Cox Robert M.³,Greenlund Sujay F.³,Plemper Richard K.³,Mitchell Deborah⁴,Marlow Joshua⁴,Andrews Meghan K.⁴,Krueger Rebecca E.⁴^ORCID,Sticher Zachary M.⁴,Kolykhalov Alexander A.⁴,Natchus Michael G.⁴,Zhou Bin²,Pelly Stephen C.¹^ORCID,Liotta Dennis C.¹^ORCID

Affiliation:

1. Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States

2. COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia 30329, United States

3. Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia 30303, United States

4. Emory Institute for Drug Development, Emory University, Atlanta, Georgia 30322, United States

Funder

Emory initiative, Biological Discovery through Chemical Innovation (BDCI)

NIH Antiviral Drug Discovery (AViDD)

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.3c00335

Reference17 articles.

1. A new coronavirus associated with human respiratory disease in China

2. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

3. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

4. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

5. The Path to Paxlovid

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions;European Journal of Medicinal Chemistry;2024-11

2. Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2;European Journal of Medicinal Chemistry;2024-10

3. Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review;Bioorganic Chemistry;2024-06

4. Proof-of-concept studies with a computationally designed M ^pro inhibitor as a synergistic combination regimen alternative to Paxlovid;Proceedings of the National Academy of Sciences;2024-04-15

5. On the origins of SARS-CoV-2 main protease inhibitors;RSC Medicinal Chemistry;2024